Antimicrobial susceptibility testing of Staphylococcus aureus isolates from patients at a tertiary hospital in Tehran, Iran, 2018–2019

Table 3 One-year cumulative antibiogram of unique Staphylococcus aureus isolates at IKHC, Tehran, Iran, 2018–2019

Antibiotic	MSSA 360 (62.5%)			MRSA 216 (37.5%)			p-value
Antibiotic	S	I	R	S	I	R	p-value
CRO	52	–	1	–	–	43	< .001
CHL	13	–	4	6	–	2	> .9
CIP	239	3	94	38	4	156	< .001
LVX	37	6	8	17	9	33	< .001
MXF	41	–	2	21	8	18	< .001
CLI	213	–	139	31	-	182	< .001
DAP	32	–	–	25	–	–	–
LZD	51	–	–	51	–	–	–
TGC	41	–	–	35	–	–	–
DOX	34	6	10	28	11	16	.20
TET	30	–	19	21	–	34	.019
ERY	184	2	138	18	3	177	< .001
GEN	298	–	14	75	2	111	< .001
IPM	32	–	1	–	–	20	< .001
NIT	17	–	–	27	3	1	.380
RIF	326	–	11	112	–	87	< .001
SXT	184	–	66	70	–	98	< .001
VAN	358	–	–	214	–	1	.375

MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant S. aureus, S sensitive, I intermediate resistance, R resistant, CRO ceftriaxone, CHL chloramphenicol, CIP ciprofloxacin, LVX levofloxacin, MXF moxifloxacin, CLI clindamycin, DAP daptomycin, LZD linezolid, TGC tigecycline, DOX doxycycline, TET tetracycline, ERY erythromycin, GEN gentamicin, IPM imipenem, NIT nitrofurantoin, RIF rifampin, SXT trimethoprim–sulfamethoxazole, VAN vancomycin

ISSN: 2047-783X